{"id":409315,"date":"2021-01-06T07:48:15","date_gmt":"2021-01-06T12:48:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409315"},"modified":"2021-01-06T07:48:15","modified_gmt":"2021-01-06T12:48:15","slug":"immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/","title":{"rendered":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients"},"content":{"rendered":"
\n

Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n PHOENIX<\/span>, Jan. 6, 2021<\/span> \/PRNewswire\/ — Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami\u00a0demonstrating that the intravenous administration of umbilical cord derived stem cells, termed “JadiCells” results in a significant survival improvement in COVID-19 patients. <\/p>\n

\n

\n
\n \"Creative
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n https:\/\/stemcellsjournals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/sctm.20-0472<\/a>\n <\/p>\n

The Phase 1\/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells\u2122 intravenously at days 0 and 3, and 12 additional patients received placebo control.\u00a0 At 28 days 91% of JadiCell\u2122 treated patients survived whereas only 42% of patients in the placebo group survived.\u00a0 There were no adverse effects associated with JadiCell\u2122 administration.<\/p>\n

“The ImmCelz\u00ae regenerative immunotherapy product is a personalized cellular therapy generated by co-culture of patient’s immune cells with stem cells.\u00a0 Due to the superior nature of the JadiCell\u2122 to other cell types, under license, we exclusively use this cell type for production of ImmCelz\u00ae,”\u00a0said Timothy Warbington<\/span>, President and CEO of Creative Medical Technology Holdings. “The data reported today strongly supports the safety and potency of the JadiCell\u2122, which also supports the validity of ImmCelz\u00ae which is ‘powered by JadiCell\u2122.’ It should be noted that neither Creative Medical Technology Holdings nor ImmCelz<\/b>\u00ae were involved in the University of Miami<\/span> trial, and that Creative Medical Technology Holdings is not pursuing COVID-19 treatments at this time,<\/b>” Mr. Warbington said further.<\/p>\n

The ImmCelz\u00ae cell therapy product has demonstrated efficacy in animal models of stroke, heart failure, autoimmunity, and liver failure.\u00a0 While the majority of companies utilize stem cell administration for therapeutic intent, ImmCelz\u00ae uses stem cells to “reprogram” patient immune cells, a process which endows the immune cells with ability to regenerate injured organs. <\/p>\n

“It has been my pleasure to work with Timothy Warbington<\/span> and his scientific team in creating a new class of cellular therapies that combines regenerative medicine with immunotherapy,” said Amit Patel<\/span>, MD, MS, inventor of the JadiCell\u2122 and co-inventor of ImmCelz\u00ae. \u00a0“The speed, precision and innovation that drives the team at Creative Medical Technology Holdings is unparalleled and I look forward to clinical translation of ImmCelz\u00ae, which is the subject of an Investigational New Drug Application that is being currently compiled.”<\/p>\n

\n About Creative Medical Technology Holdings<\/b>\n <\/p>\n

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative stem cell technology in the fields of Immunotherapy, urology, neurology and orthopedics, and is quoted on the OTC Markets under the symbol CELZ. For further information about the company, please visit\u00a0www.creativemedicaltechnology.com<\/a>.\u00a0<\/b><\/p>\n

\n Forward Looking Statements<\/b>\n <\/p>\n

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at\u00a0www.sec.gov<\/a>.<\/p>\n

\n Creativemedicaltechnology.com<\/a>
\n
\n www.StemSpine.com<\/a>
\n
\n www.Caverstem.com<\/a>
\n
\n www.Femcelz.com<\/a>\n <\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients-301201752.html<\/a><\/p>\n

SOURCE Creative Medical Technology Holdings, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell PR Newswire PHOENIX, Jan. 6, 2021 \/PRNewswire\/ — Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami\u00a0demonstrating that the intravenous administration of umbilical cord derived stem cells, termed “JadiCells” results in a significant survival improvement in COVID-19 patients. https:\/\/stemcellsjournals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/sctm.20-0472 The Phase 1\/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells\u2122 intravenously at days 0 and 3, and 12 additional patients received placebo control.\u00a0 At 28 days 91% of JadiCell\u2122 treated patients survived whereas only 42% of patients in the placebo group survived.\u00a0 There were no adverse effects associated with JadiCell\u2122 administration. “The ImmCelz\u00ae regenerative … <\/p>\n

Continue reading “ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409315","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell PR Newswire PHOENIX, Jan. 6, 2021 \/PRNewswire\/ — Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami\u00a0demonstrating that the intravenous administration of umbilical cord derived stem cells, termed “JadiCells” results in a significant survival improvement in COVID-19 patients. https:\/\/stemcellsjournals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/sctm.20-0472 The Phase 1\/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells\u2122 intravenously at days 0 and 3, and 12 additional patients received placebo control.\u00a0 At 28 days 91% of JadiCell\u2122 treated patients survived whereas only 42% of patients in the placebo group survived.\u00a0 There were no adverse effects associated with JadiCell\u2122 administration. “The ImmCelz\u00ae regenerative … Continue reading "ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T12:48:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients\",\"datePublished\":\"2021-01-06T12:48:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/\"},\"wordCount\":575,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/\",\"name\":\"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\",\"datePublished\":\"2021-01-06T12:48:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/","og_locale":"en_US","og_type":"article","og_title":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients - Market Newsdesk","og_description":"Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell PR Newswire PHOENIX, Jan. 6, 2021 \/PRNewswire\/ — Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami\u00a0demonstrating that the intravenous administration of umbilical cord derived stem cells, termed “JadiCells” results in a significant survival improvement in COVID-19 patients. https:\/\/stemcellsjournals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/sctm.20-0472 The Phase 1\/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells\u2122 intravenously at days 0 and 3, and 12 additional patients received placebo control.\u00a0 At 28 days 91% of JadiCell\u2122 treated patients survived whereas only 42% of patients in the placebo group survived.\u00a0 There were no adverse effects associated with JadiCell\u2122 administration. “The ImmCelz\u00ae regenerative … Continue reading \"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T12:48:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients","datePublished":"2021-01-06T12:48:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/"},"wordCount":575,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/","name":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","datePublished":"2021-01-06T12:48:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immcelz-stem-cell-component-demonstrated-efficacious-in-fda-double-blind-placebo-controlled-clinical-trial-of-advanced-covid-19-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409315"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409315\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}